Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.50 |
| ▸ | HRH2 | P25021 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7994498 | 0.87 | HRH3 (0.51) | RAB9AMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL21663340 | 0.83 | LTA4H (0.67) | MEN1KMT2AALDH1A1CYP2D6HRH3 | |
| SCHEMBL13493053 | 0.81 | RAB9A (0.62) | RAB9AMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL7998333 | 0.80 | LTA4H (0.43) | ALDH1A1HRH3HRH2HRH1LTA4H | |
| SCHEMBL29204593 | 0.79 | HRH3 (0.62) | MEN1KMT2AALDH1A1CYP2D6HRH3 | |
| Hydrochloric Acid SCHEMBL29204587 | 0.78 | HRH3 (0.60) | MEN1KMT2AALDH1A1CYP2D6HRH3 | |
| SCHEMBL11862156 | 0.78 | HRH3 (0.49) | RAB9AMEN1KMT2AALDH1A1HRH3 | |
| SCHEMBL21120213 | 0.75 | KMT2A (0.47) | RAB9AMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL24008438 | 0.73 | RAB9A (0.94) | RAB9AMEN1KMT2AALDH1A1CYP2D6 | |
| SCHEMBL9499075 | 0.73 | NR5A1 (0.61) | RAB9ALTA4HNPC1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | GENZYME CORPORATION | 2018-04-05 | — | — | US | disclosed |
| WO-2009117150-A2 | METHOD OF TREATING LUPUS WITH CERAMIDE DERIVATIVES | GENZYME CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093981-A1 | 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors | ASAH2, GBA1, GAA | RAB9A 2280/4885MEN1 3973/4885KMT2A 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.